Epigallocatechingallate (EGCG) in Cardiac AL Amyloidosis

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2012
In a proportion of patients with AL amyloidosis there is no improvement of cardiac function despite hematologic response to treatment. The aim of the study is to assess whether treatment with EGCG increases the rate of cardiac response in patients with AL amyloidosis who completed chemotherapy.
Epistemonikos ID: 1cc83d835c0b80eee4ee2c3161827c0f69dff9c5
First added on: May 10, 2024